Clinical Trials Logo

Clinical Trial Summary

This is a phase 1 open-label pharmacodynamics study in healthy adults. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, has an impact on delivery location. The secondary objective is to evaluate delivery with fasting versus fed status.


Clinical Trial Description

This is a pharmacodynamics study in healthy adult males. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, impacts the location and time of initial and complete disintegration of the drug product. The secondary objective is to evaluate delivery with fasting versus fed status. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03121339
Study type Interventional
Source Vaxart
Contact
Status Completed
Phase Phase 1
Start date March 31, 2017
Completion date April 3, 2018